1Abramson Family Cancer Research Institute; 2Perelman School of Medicine, University of Pennsylvania; 3The Wistar Institute, Philadelphia, Pennsylvania; Departments of 4Pharmacology and Cancer Biology and 5Radiation Oncology, Duke University Medical Center, Durham, North Carolina; 6Howard Hughes Medical Institute; 7Department of Surgery, Massachusetts General Hospital, Boston, Massachusetts; and 8Memorial Sloan-Kettering Cancer Center, New York, New York.
Cancer Discov. 2013 Oct;3(10):1190-205. doi: 10.1158/2159-8290.CD-13-0118. Epub 2013 Aug 1.
Intratumoral hypoxia and expression of hypoxia-inducible factor-1α (HIF-1α) correlate with metastasis and poor survival in patients with sarcoma. We show here that hypoxia controls sarcoma metastasis through a novel mechanism wherein HIF-1α enhances expression of the intracellular enzyme procollagen-lysine, 2-oxoglutarate 5-dioxygenase 2 (PLOD2). We show that loss of HIF-1α or PLOD2 expression disrupts collagen modification, cell migration, and pulmonary metastasis (but not primary tumor growth) in allograft and autochthonous LSL-Kras(G12D/+); Trp53(fl/fl) murine sarcoma models. Furthermore, ectopic PLOD2 expression restores migration and metastatic potential in HIF-1α-deficient tumors, and analysis of human sarcomas reveals elevated HIF1A and PLOD2 expression in metastatic primary lesions. Pharmacologic inhibition of PLOD enzymatic activity suppresses metastases. Collectively, these data indicate that HIF-1α controls sarcoma metastasis through PLOD2-dependent collagen modification and organization in primary tumors. We conclude that PLOD2 is a novel therapeutic target in sarcomas and successful inhibition of this enzyme may reduce tumor cell dissemination.
Undifferentiated pleomorphic sarcoma (UPS) is a commonly diagnosed and particularly aggressive sarcoma subtype in adults, which frequently and fatally metastasizes to the lung. Here, we show the potential use of a novel therapeutic target for the treatment of metastatic UPS, specifi cally the collagen-modifying enzyme PLOD2.
肿瘤内缺氧和缺氧诱导因子-1α(HIF-1α)的表达与肉瘤患者的转移和不良预后相关。我们在这里表明,缺氧通过一种新的机制控制肉瘤转移,其中 HIF-1α增强了细胞内酶脯氨酸-赖氨酸、2-氧戊二酸 5-二加氧酶 2(PLOD2)的表达。我们表明,HIF-1α或 PLOD2 表达的缺失破坏了同种异体和自发 LSL-Kras(G12D/+);Trp53(fl/fl)鼠肉瘤模型中的胶原修饰、细胞迁移和肺转移(但不影响原发性肿瘤生长)。此外,外源性 PLOD2 表达恢复了 HIF-1α缺陷肿瘤的迁移和转移潜能,对人类肉瘤的分析显示,转移性原发性病变中 HIF1A 和 PLOD2 的表达升高。PLOD 酶活性的药理学抑制可抑制转移。总之,这些数据表明,HIF-1α通过 PLOD2 依赖性胶原修饰和原发性肿瘤中的组织控制肉瘤转移。我们得出结论,PLOD2 是肉瘤的一个新的治疗靶点,成功抑制这种酶可能会减少肿瘤细胞的扩散。
未分化多形性肉瘤(UPS)是成人中常见诊断和特别侵袭性的肉瘤亚型,常致命地转移到肺部。在这里,我们展示了一种新的治疗靶点在治疗转移性 UPS 中的潜在用途,特别是胶原修饰酶 PLOD2。